Consequently, true ERBB2 amplifications may go uncalled when ctF is lower—a common circumstance in biliary tract cancers—whereas tissue CGP, which is not limited by ctF, typically provides deeper and more uniform coverage and a broader dynamic range for copy-number inference in FFPE, improving sensitivity for ERBB2 amplification. Here, ERBB2 is linked to biliary tract cancer.